Cargando…

In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment

Background: Melanoma is the most lethal of all skin-related cancers with incidences continuously rising. Novel therapeutic approaches are urgently needed, especially for the treatment of metastasizing or therapy-resistant melanoma. CAR-modified immune cells have shown excellent results in treating h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grote, Stefan, Ureña-Bailén, Guillermo, Chan, Kenneth Chun-Ho, Baden, Caroline, Mezger, Markus, Handgretinger, Rupert, Schleicher, Sabine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145105/ https://www.ncbi.nlm.nih.gov/pubmed/33925968 http://dx.doi.org/10.3390/cells10051020

Ejemplares similares

Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL
por: Ureña-Bailén, Guillermo, et al.
Publicado: (2022)

Adapter Chimeric Antigen Receptor (AdCAR)-Engineered NK-92 Cells for the Multiplex Targeting of Bone Metastases
por: Grote, Stefan, et al.
Publicado: (2021)

Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting
por: Grote, Stefan, et al.
Publicado: (2020)

CRISPR medicine for blood disorders: Progress and challenges in delivery
por: Mohammadian Gol, Tahereh, et al.
Publicado: (2023)

Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia
por: Pfeiffer, Matthias Manuel, et al.
Publicado: (2013)

CRISPR-Cas9-Based Gene Knockout of Immune Checkpoints in Expanded NK Cells
por: Mohammadian Gol, Tahereh, et al.
Publicado: (2023)

Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer
por: Cao, Bihui, et al.
Publicado: (2021)

NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML
por: Schlegel, Patrick, et al.
Publicado: (2015)

Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells
por: Pinz, Kevin G., et al.
Publicado: (2017)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016)

Somatic Reversion of a Novel IL2RG Mutation Resulting in Atypical X-Linked Combined Immunodeficiency
por: Hou, Yujuan, et al.
Publicado: (2021)

Challenges in Gene Therapy for Somatic Reverted Mosaicism in X-Linked Combined Immunodeficiency by CRISPR/Cas9 and Prime Editing
por: Hou, Yujuan, et al.
Publicado: (2022)

Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma
por: Zhang, Qing, et al.
Publicado: (2017)

CAR NK-92 cell–mediated depletion of residual TCR(+) cells for ultrapure allogeneic TCR-deleted CAR T-cell products
por: Kath, Jonas, et al.
Publicado: (2023)

Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate Cancer
por: Montagner, Isabella Monia, et al.
Publicado: (2020)

Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway
por: Althaus, Jonas, et al.
Publicado: (2023)

Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models
por: Zhang, Qing, et al.
Publicado: (2018)

“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
por: Mitwasi, Nicola, et al.
Publicado: (2020)

Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas
por: Zuo, Pengcheng, et al.
Publicado: (2023)

Corrigendum to “Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models”
por: Zhang, Qing, et al.
Publicado: (2019)

CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models
por: Timpanaro, Andrea, et al.
Publicado: (2023)

Cordycepin Sensitizes Cholangiocarcinoma Cells to Be Killed by Natural Killer-92 (NK-92) Cells
por: Panwong, Suthida, et al.
Publicado: (2021)

Low Energy Electron Irradiation Is a Potent Alternative to Gamma Irradiation for the Inactivation of (CAR-)NK-92 Cells in ATMP Manufacturing
por: Walcher, Lia, et al.
Publicado: (2021)

Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
por: Roex, Gils, et al.
Publicado: (2022)

ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma
por: Heim, Catrin, et al.
Publicado: (2023)

Influence of Galectin-9 Treatment on the Phenotype and Function of NK-92MI Cells in the Presence of Different Serum Supplements
por: Meggyes, Matyas, et al.
Publicado: (2021)

Removal of CD276(+) cells from haploidentical memory T-cell grafts significantly lowers the risk of GVHD
por: Hashimoto, Hisayoshi, et al.
Publicado: (2021)

Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer
por: Ao, Xiang, et al.
Publicado: (2019)

Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells
por: Luo, Hong, et al.
Publicado: (2019)

Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123
por: Morgan, Michael A., et al.
Publicado: (2021)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer
por: Wang, Xiaohui, et al.
Publicado: (2023)

Fibroblasts Impair Migration and Antitumor Activity of NK-92 Lymphocytes in a Melanoma-on-Chip Model
por: Iaia, Ilenia, et al.
Publicado: (2022)

Eradication of Pulmonary Aspergillosis in an Adolescent Patient Undergoing Three Allogeneic Stem Cell Transplantations for Acute Lymphoblastic Leukemia
por: Döring, Michaela, et al.
Publicado: (2012)

P33. NK-92 cellular immunotherapy as an alternative to donor derived peripheral blood NK cells
por: Klingemann, H
Publicado: (2014)

Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
por: Klingemann, Hans, et al.
Publicado: (2016)

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
por: Kilgour, Marisa K., et al.
Publicado: (2023)

Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies
por: Krug, Adrien, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vkddn26d9ee31mdt61vjqpvvq2